Screening method for anticancer drug

1. A screening method for selecting an anticancer drug effective in cancer in which β-catenin participates, the method comprising the steps of:

(a) providing a number of candidate compounds;

(b) measuring the kinase activity of the TRAF2 and NCK interacting kinase in the presence of each candidate compound;

(c) determining that a candidate compound is an anticancer drug candidate compound when the measured kinase activity in the presence of the candidate compound is lower than kinase activity of TRAF2 and NCK interacting kinase in the absence of the candidate compound; and

(d) selecting an anticancer drug from among the candidate compounds determined to be anticancer drug candidate compounds.

2. The screening method for an anticancer drug according to claim 1 , wherein the candidate compound blocks the kinase activity of the TRAF2 and NCK interacting kinase by interfering with binding of ATP to the ATP binding site of the TRAF2 and NCK interacting kinase.

3. The screening method for an anticancer drug according to claim 1 , wherein the cancer is selected from the group consisting of colon cancer, ovarian cancer, endometrial cancer, childhood brain tumor, liver cancer, hepatoblastoma and stomach cancer.

4. The screening method for an anticancer drug according to claim 1 , wherein, in step (a) the number of candidate compounds consists of compounds that can conform to an ATP binding site of the TRAF2 and NCK interacting kinase.

5. A screening method for selecting an anticancer drug effective in cancer in which β-catenin participates, the method comprising the steps of:

(a) providing a number of candidate compounds;

(b) measuring a degree of interaction between the TRAF2 and NCK interacting kinase and the β-catenin/T-cell factor-4 transcription complex in the presence of each candidate compound;

(c) determining that a candidate compound is an anticancer drug candidate compound when the measured degree of interaction in the presence of the candidate compound is less than a degree of interaction between TRAF2 and NCK interacting kinase and a β-catenin/T-cell factor-4 transcription complex in the absence of the candidate compound; and

(d) selecting an anticancer drug from among the candidate compounds determined to be anticancer drug candidate compounds.

6. The screening method for an anticancer drug according to claim 5 , wherein the degree of interaction between the TRAF2 and NCK interacting kinase and the β-catenin/T-cell factor-4 transcription complex either in the presence of the candidate compound or in the absence of the candidate compound is measured using a two-hybrid assay.

7. The screening method for an anticancer drug according to claim 5 , wherein the degree of interaction between the TRAF2 and NCK interacting kinase and the β-catenin/T-cell factor-4 transcription complex either in the presence of the candidate compound or in the absence of the candidate compound is measured using an antigen-antibody reaction.

8. The screening method for an anticancer drug according to claim 5 , wherein the degree of interaction between the TRAF2 and NCK interacting kinase and the β-catenin/T-cell factor-4 transcription complex in the presence of the candidate compound is measured by culturing cells expressing the TRAF2 and NCK interacting kinase, the β-catenin, and the T-cell factor-4 in the presence of the candidate compound, and wherein the candidate compound is determined to be an anticancer drug when cell proliferation of the cultured cells in the presence of the candidate compound is inhibited compared to cell proliferation when cells expressing the TRAF2 and NCK interacting kinase, the β-catenin, and the T-cell factor-4 are cultured in the absence of the candidate compound.

9. The screening method for an anticancer drug according to claim 5 , wherein the cancer is selected from the group consisting of colon cancer, ovarian cancer, endometrial cancer, childhood brain tumor, liver cancer, hepatoblastoma and stomach cancer.